RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter ended June 30, 2010
Currency: Indian Rupees (Rs.) with U.S. Dollar (U.S.$) convenience translation at Rs.46.41 = U.S.$1.00
Business Overview: DRL is a leading India-based pharmaceutical company operating in Pharmaceutical Services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Principal operations include manufacturing in India and Mexico, with marketing in India, Russia, the U.S., Europe, and other regions.

Key Financial Metrics

Note: Total Debt calculated as Short-term borrowings (Rs. 6,101) + Long-term borrowings current portion (Rs. 3,515) + Long-term borrowings non-current (Rs. 4,226) + Obligations under finance leases (Rs. 234).

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 7% to Rs. 16,831 million. Excluding the impact of Sumatriptan (authorized generic of Imitrex) which ended exclusivity in the prior year, organic revenue grew 4%.
• Segment Performance:
  • Global Generics: Revenues fell 8% to Rs. 11,917 million. North America revenues dropped 35% (excluding Sumatriptan, down 2%) due to currency headwinds and lower sales of Fexofenadine and Finasteride. Russia revenues surged 35%.
  • PSAI: Revenues declined 8% to Rs. 4,499 million due to customer inventory reductions and price erosion in the global API market.
• Margin Compression: Gross margin decreased from 56% to 53%, primarily due to the loss of high-margin Sumatriptan sales and adverse foreign exchange impacts (Rupee appreciation).
• Profitability: Net profit decreased 14% to Rs. 2,096 million. Operating profit fell 20% to Rs. 2,625 million.
• Cash Flow: Operating cash flow dropped significantly to Rs. 858 million (from Rs. 4,315 million) due to lower operating profits, increased receivables, and higher inventory build-up for new product launches.
• Foreign Exchange: A foreign exchange loss of Rs. 224 million was recorded, largely driven by the depreciation of the Russian rouble against the U.S. dollar.

Guidance, Outlook, Risks, and Unusual Items

• Outlook & Strategy: Management is focusing on market share expansion in India and Russia, and rationalizing costs in Germany following workforce reductions. The company is increasing vertically integrated products to compete in German tenders.
• Recent Developments:
  • GSK Acquisition: Agreed to acquire GSK's oral penicillin facility in the U.S. and certain product portfolios (expected consummation before June 30, 2011).
  • Brazil Sale: Sold marketing authorizations and dossiers for a product portfolio in Brazil to GSK Brazil for Rs. 604 million (U.S.$13), with an upfront payment deferred over 3 years.
  • Bonus Debentures: Shareholders approved a scheme to issue bonus debentures (6 for 1 equity share), pending regulatory approvals.
• Risks & Contingencies:
  • Patent Litigation: Facing injunctions and litigation regarding Fexofenadine (U.S.), Alendronate Sodium (Germany), Olanzapine (Canada), and Erlotinib (India). A preliminary injunction was granted against the launch of Fexofenadine-pseudoephedrine in the U.S.
  • Regulatory: Ongoing investigations by U.S. Attorneys General regarding marketing practices of Ranitidine, Fluoxetine, and Buspirone.
  • German Market: Continued pressure from competitive bidding tenders leading to a "high volume, low margin" business model.
• Unusual Items:
  • Sumatriptan Impact: The prior year period included Rs. 2,054 million in high-margin revenue from Sumatriptan, which is not comparable to the current period.
  • German Restructuring: Significant SG&A reduction in the current period due to workforce reductions implemented in the prior fiscal year.

Investor Verification Checklist

• Sumatriptan Run-rate: Verify the sustainability of revenue growth excluding the one-time Sumatriptan exclusivity benefit from the prior year.
• U.S. Litigation Status: Monitor the outcome of the Fexofenadine preliminary injunction and trial scheduled for January 2011, as this impacts a key U.S. product.
• Currency Exposure: Assess the impact of Rupee appreciation and Russian Rouble volatility on future earnings translation.
• German Restructuring: Confirm if SG&A reductions in Germany are stabilizing margins amidst aggressive price competition.
• Inventory Levels: Review the rationale for the Rs. 1,497 million increase in inventory and its impact on working capital efficiency.
• GSK Transaction: Track the regulatory approval timeline and financial terms of the U.S. manufacturing site acquisition.